Epicet-1000 XR Tablet Tablet

Epicet-1000 XR Tablet সম্পর্কে

Epicet-1000 XR Tablet একটি ট্যাবলেট ঔষধ, যার জেনেরিক নাম Levetiracetam এবং শক্তি ১০০০ mg। এটি তৈরি করে Renata PLC। Epicet-1000 XR Tablet-এর সাথে Levetiracetam-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।

Levetiracetam-এর ৩৪টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। সবচেয়ে কম দাম Citazar 250 mg Tablet-এর, প্রতি ইউনিট ৳ ১৫.১১।

Epicet-1000 XR Tablet কী?

Epicet-1000 XR Tablet is an extended-release tablet made by Renata PLC. It contains levetiracetam 1000 mg, a medicine from the anti-epileptic group. Levetiracetam is used to treat partial-onset seizures, which may or may not spread to the whole body. It can be prescribed alone or together with other epilepsy medicines. Exactly how it is used depends on the person's condition, and the doctor decides the dose and course. Always follow the doctor's instructions and do not change or stop the medicine on your own.

Epicet-1000 XR Tablet-এর ব্যবহার

Epicet-1000 XR Tablet is used for partial-onset seizures, a type of epilepsy where fits start in one part of the brain. It may be prescribed on its own or added to other epilepsy medicines. The doctor decides whether it suits a particular person and how long it should be taken. Never start, stop or change the medicine without the doctor's advice.

Epicet-1000 XR Tablet কীভাবে ব্যবহার করবেন

Take Epicet-1000 XR Tablet as the doctor tells you. Extended-release tablets are usually swallowed whole and should not be crushed or chewed, but ask the doctor or pharmacist to confirm. Do not change the amount or stop suddenly, because stopping epilepsy medicine suddenly can be harmful. If you miss a dose, ask the doctor or pharmacist what to do. The doctor decides the dose and course.

Epicet-1000 XR Tablet-এর পার্শ্বপ্রতিক্রিয়া

Some people may feel sleepy, weak or dizzy, or may get an infection. Children may also feel tired, irritable or aggressive, have a blocked nose or eat less. Report any side effect that worries you to the doctor. Serious problems are possible but uncommon; ask the doctor or pharmacist about anything unusual. The doctor can advise on what to watch for and whether the medicine needs review.

সতর্কতা ও নিরাপত্তা

Tell the doctor before taking Epicet-1000 XR Tablet if you have kidney or liver problems, because the doctor may need to check your kidney function and adjust the plan. Rarely, this medicine has been linked with kidney injury and with lowered blood cell counts, so report unusual tiredness, fever or bruising. It is not recommended in pregnancy or in women who could become pregnant and are not using contraception unless the doctor considers it necessary. It passes into breast milk, so breastfeeding is generally not recommended; discuss this with the doctor. Anyone allergic to levetiracetam or similar medicines should not take it. Ask the doctor or pharmacist if you have questions.

সাধারণ প্রশ্ন

What is Epicet-1000 XR Tablet used for and what kind of medicine is it?

It is an anti-epileptic medicine containing levetiracetam 1000 mg. It is used for partial-onset seizures, either alone or with other epilepsy medicines. The doctor decides if it is suitable and how long it should be taken.

Which medicines may interact with Epicet-1000 XR Tablet?

Clinical studies in adults found that levetiracetam did not change the blood levels of several other epilepsy medicines, and those medicines did not change how levetiracetam behaved. Probenecid has been shown to affect the clearance of a levetiracetam metabolite. Tell your doctor or pharmacist about every medicine you take, including other epilepsy medicines.

How should Epicet-1000 XR Tablet be stored?

Keep it at a cool temperature not exceeding 25°C, in a dry place and protected from light. Keep it out of the reach of children. Do not use it after the expiry date. If you are unsure how to store it, ask your pharmacist.

Can I stop Epicet-1000 XR Tablet on my own?

No. Stopping epilepsy medicine suddenly can be harmful. Always talk to the doctor before changing or stopping it, even if you feel well. The doctor will decide the right plan for you and can answer questions about how long you need to take it.

Tablet
জেনেরিক নাম
Levetiracetam
শক্তি
1000 mg
ডোজ ফর্ম
Tablet
প্রস্তুতকারক
Renata PLC.

নির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy-
  • in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
  • ... Read more
Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy-
  • in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
  • in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
  • in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

মাত্রা ও সেবনবিধি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Adults and adolescents from 16 years of age: The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.

Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.

Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.

  • Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
  • Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
  • Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.

ঔষধের মিথষ্ক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Antiepileptic medicinal products: Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.

Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.

Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.

Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.

Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.

প্রতিনির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients.

পার্শ্ব প্রতিক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Most common adverse reactions (incidence ≥ 5% more than placebo) include:
  • Adult patients: somnolence, asthenia, infection and dizziness
  • Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability

গর্ভাবস্থায় ও স্তন্যদানকালে

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary. Levetiracetam is excreted in human breast milk. Therefore, breastfeeding is not recommended. However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding. No impact on fertility was detected in animal studies. No clinical data are available, the potential risk for humans is unknown.

সতর্কতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Renal impairment: The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection.

Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.

Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.

Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.

Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.

মাত্রাধিক্যতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses. After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specifc antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60 % for levetiracetam and 74% for the primary metabolite.

সংরক্ষণ

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Store at a cool temperature (not exceeding 25°C) and dry place, protected from light.

বিকল্প ব্র্যান্ড: Levetiracetam

একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।

Citazar Tablet

250 mg

Levetiracetam

Advanced Chemical Industries PLC

৳ ১৪.৮১ ৳ ১৫.১১ ২% ছাড় প্রতি ইউনিট

Iracet Tablet

250 mg

Levetiracetam

Square Pharmaceuticals PLC.

৳ ১৫.৬৮ ৳ ১৬.০০ ২% ছাড় প্রতি ইউনিট

Citazar Tablet

500 mg

Levetiracetam

Advanced Chemical Industries PLC

৳ ২৯.৪ ৳ ৩০.০০ ২% ছাড় প্রতি ইউনিট

Levefix 500 mg Tablet

500 mg

Levetiracetam

Opsonin Pharma Limited

৳ ২৯.৪ ৳ ৩০ ২% ছাড় প্রতি ইউনিট

Iracet Tablet

500 mg

Levetiracetam

Square Pharmaceuticals PLC.

৳ ৩১.৩৬ ৳ ৩২.০০ ২% ছাড় প্রতি ইউনিট

Citazar Suspension

100 mg/ml

Levetiracetam

Advanced Chemical Industries PLC

দাম দেওয়া নেই

Citazar Tablet

1000 mg

Levetiracetam

Advanced Chemical Industries PLC

দাম দেওয়া নেই

Citazar Tablet

750 mg

Levetiracetam

Advanced Chemical Industries PLC

দাম দেওয়া নেই

Citazar Iv Injection

500 mg/5 ml

Levetiracetam

Advanced Chemical Industries PLC

দাম দেওয়া নেই

সব দেখুন ৩৪ ব্র্যান্ড

ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।